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Abstract
Background: Glutamate and g-aminobutyric acid (GABA) transporters play important roles in balancing excitatory
and inhibitory signals in the brain. Increasing evidence suggest that they may act concertedly to regulate
extracellular levels of the neurotransmitters.
Results: Here we present evidence that glutamate uptake-induced release of GABA from astrocytes has a direct
impact on the excitability of pyramidal neurons in the hippocampus. We demonstrate that GABA, synthesized from
the polyamine putrescine, is released from astrocytes by the reverse action of glial GABA transporter (GAT)
subtypes GAT-2 or GAT-3. GABA release can be prevented by blocking glutamate uptake with the non-
transportable inhibitor DHK, confirming that it is the glutamate transporter activity that triggers the reversal of
GABA transporters, conceivably by elevating the intracellular Na+ concentration in astrocytes. The released GABA
significantly contributes to the tonic inhibition of neurons in a network activity-dependent manner. Blockade of the
Glu/GABA exchange mechanism increases the duration of seizure-like events in the low-[Mg2+] in vitro model of
epilepsy. Under in vivo conditions the increased GABA release modulates the power of gamma range oscillation in
the CA1 region, suggesting that the Glu/GABA exchange mechanism is also functioning in the intact hippocampus
under physiological conditions.
Conclusions: The results suggest the existence of a novel molecular mechanism by which astrocytes transform
glutamatergic excitation into GABAergic inhibition providing an adjustable, in situ negative feedback on the
excitability of neurons.
Background
Glial cells have long been considered to have only a
supporting role in the central nervous system. Substan-
tial advances in the past two decades, however, shed
light on the various physiological functions they perform
and led to the current view that they are active partici-
pants of the tripartite synapse [1,2], consisting of the
presynaptic and postsynaptic neurons as well as the glial
cells, in particular astrocytes. Several studies demon-
strated the ability of astrocytes to sense, respond to and
regulate neuronal function. Importantly, astrocytes pos-
sess the complete set of membrane proteins to detect g-
aminobutyric acid (GABA) and glutamate (Glu), the
major inhibitory and excitatory neurotransmitters of the
brain, respectively. They express GABA [3] and Glu [4]
transporters, as well as ionotropic and metabotropic
GABA [5-7] and Glu receptors [8]. Activation of these
proteins initiates various pathways in the glial cells
including Ca2+signalling [9,10], eventually leading to the
release of GABA or Glu in either vesicular [11] or non-
vesicular [12] manner.
Among the various mechanisms by which astrocytes
control neuronal functions, regulation of tonic inhibition
may play a major role. GABAergic inhibition of neurons
can be divided into phasic and tonic components. The
phasic component is composed of discrete, transient
inhibitory postsynaptic currents (IPSCs) corresponding
to vesicular release events from the presynaptic axon
terminal. These currents are mediated by low-affinity
GABAA receptors in the synapse. In contrast, the persis-
tent tonic GABAergic inhibition is mediated by high-
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affinity, slowly desensitizing, extrasynaptic GABAA
receptors experiencing low concentrations of ambient
GABA [13]. Tonic inhibition has recently been demon-
strated to have paramount importance. By modulating
the membrane conductance of the postsynaptic neurons,
tonic inhibition greatly influences the excitability of sin-
gle neurons as well as networks [14]. Moreover, tonic
inhibition gains increasing attention in the treatment of
pathophysiological conditions, like epilepsy [15] or
stroke [16]. Despite its significance, however, the source
of GABA that generates tonic current is still a matter of
debate. Some groups claim that ambient GABA concen-
tration is set almost exclusively by vesicular GABA
escaping the synapse [17], while others argue that
release from astrocytes constitutes a significant source
for extrasynaptic GABA [18].
In addition to the well-known interplay between the
GABAergic and glutamatergic systems at the cellular and
sub-cellular levels [19-23], we previously demonstrated
the existence of a direct interaction between GABAergic
and glutamatergic neurotransmissions at the molecular
level [24]. We showed that uptake of Glu triggered an
elevation in the extracellular level of GABA both in
vitro and in vivo. The direct coupling between excitatory
and inhibitory neurotransmitter transporters was found
to be independent of Glu receptor-mediated depolariza-
tion, external presence of Ca2+ and glutamate decarbox-
ylase activity. It was abolished in the presence of non-
transportable blockers of either glial Glu or GABA
transporters, suggesting that the concerted action of
these transporters underlies the process [24].
In the present study, we explore the potential physiolo-
gical and pathophysiological role of the Glu/GABA
exchange process in freshly isolated hippocampal slices
and in the hippocampus in vivo. We demonstrate that the
GABA released from astrocytes in response to Glu uptake
significantly contributes to the tonic inhibition of neurons
during intense excitation. Moreover, the generated tonic
inhibition emerges in line with the increasing network
activity, providing a tuneable, in situ negative feedback.
We also describe the molecular mechanism by which glu-
tamatergic neurotransmission is transformed into
GABAergic inhibition and identify the source of releasable
astrocytic GABA. We show that the negative feedback
control of astrocytes on neuronal excitability offers signifi-
cant neuroprotection during seizure-like activity. The phy-
siological importance of the Glu/GABA exchange
mechanism is further substantiated by in vivo results,
which are in accordance with our in vitro observations.
Results
Glial Glu and GABA transporters are colocalized
We previously demonstrated that Glu uptake evokes
GABA release by reversal of glial GABA transporter
(GAT) subtypes GAT-2 or GAT-3 in brain homogenates
[24]. In the same study we also showed by costainings
with the neuronal and glial markers NeuN, synaptho-
physin and GFAP that, in accordance with the literature
[25], GAT-3 transporters are expressed mostly in astro-
cytes [24]. Furthermore, ultrastructural [25] and func-
tional [26] data from other groups showed that GAT-3
is expressed on glial processes ensheathing excitatory
synapses. Since the major glutamate transporters
EAAT1 and EAAT2 are also localized to astrocytic end
feet [27,28], it is a viable hypothesis that GAT-3 and
EAATs are coexpressed on astrocytic end feet surround-
ing glutamatergic synapses.
To evaluate the possibility that GABA and Glu trans-
porters colocalize in hippocampal slices, we performed
GAT-3/EAAT2 double immunostaining. Both stainings
showed punctate structures throughout the hippocam-
pus. In accordance with data from other groups, EAAT2
immunoreactivity was most prominent in the dentate
gyrus and in the pyramidal cell layer of the CA1 [27,28],
while GAT-3 was mainly localized to the pyramidal
layer of CA1 and CA3 [25]. Most importantly, the
EAAT2 immunoreactivity was largely colocalized with
GAT-3 in the pyramidal cell layer and stratum radiatum
of both the CA1 and CA3 (Figure 1) region of the hip-
pocampus. The immunoreactive puncta surrounded the
cell bodies (Figure 1A, C) and dendrites (Figure 1B) of
the glutamatergic pyramidal neurons at presumed astro-
cytic end feet sites. To quantify the degree of colocaliza-
tion, we determined the Pearson’s coefficient (Rr) and
the Mander’s coefficient (R) [29]. The quantification
showed high correlation between EAAT2 and GAT-3
immunoreactivity (Rr = 0.600, 0.516 and 0.566; R =
0.916, 0.893 and 0.764 for CA1 str. pyramidale, CA1 str.
radiatum and CA3 str. pyramidale, respectively). The
immunohistochemical analysis of the localization of
GABA and Glu transporters, therefore, confirms the
possibility of close, molecular-level interaction between
EAAT2 and GAT-2/3 glial cells. Although a minor frac-
tion of GAT-2/3 and EAAT2 may be expressed on neu-
rons as well [30,31], their density in neurons is much
lower than in astrocytes; therefore, they are unlikely to
affect each other’s activity even if they were colocalized.
Glu uptake-induced GABA release through glial
transporters contributes to tonic inhibition of neurons
Since the glial GAT-2/3 transporters are facing the
extrasynaptic space instead of the synapse [26], the
potential consequence of a transporter mediated glial
GABA release is the activation of extrasynaptic GABAA
receptors and the subsequent enhancement of tonic
inhibition on neurons. To investigate the contribution of
glial GATs to neuronal GABAergic currents, we per-
formed electrophysiological recordings from CA1
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pyramidal cells of freshly isolated rat hippocampal slices
under control conditions and during enhanced activity
of the glutamatergic synapses.
The impact of transporter mediated glial GABA
release on neuronal tonic inhibition was assessed by
blocking the glial GABA transporters with the GAT-2/
3-specific, non-transportable inhibitor SNAP-5114 (100
μM, [9,32]) while measuring the GABAergic holding
current in CA1 pyramidal neurons that are extensively
covered by a glial sheat [33]. We used CsMeSO3-based
pipette solution to isolate GABAergic (outward directed)
currents in voltage clamped configuration by applying 0
mV holding potential to eliminate glutamatergic cur-
rents. Synaptic currents were identified as GABAergic
inhibitory postsynaptic currents (IPSCs) and baseline
currents were validated as a measure of tonic GABAer-
gic currents by adding the GABAA antagonist picrotoxin
(100 μM) at the end of 43 of 154 experiments (see
Methods). The GAT-2/3 mediated tonic current compo-
nent was calculated as the change in the holding current
in response to SNAP-5114 application.
Under control condition we did not observe signifi-
cant change in the tonic current following blockade of
GAT-2/3 transporters by 100 μM SNAP-5114 (Figures
2A and 3A). Local initiation of Glu release in the CA1
region by applying stimuli to the Schaffer collaterals by
a bipolar Tungsten electrode also did not reveal a GAT-
2/3 mediated tonic current component (average holding
Figure 1 Glial GABA and Glu transporters are colocalized. GAT-3 (red) and EAAT2 (green) immunoreactive small puncta surround neuronal
cell bodies and dendrites in the CA1 str. pyramidale (top), CA1 str. radiatum (middle) and CA3 str. pyramidale (bottom) regions. GAT-3 and
EAAT2 immunoreactivites show almost complete colocalization (yellow) around the soma and on the dendrites of presumable pyramidal cells.
Right: higher magnification of boxed region in merged image. R: str. radiatum, P: str. pyramidale, O: str. oriens. Scale bar = 50 μm (GAT-3, EAAT2
and overlay) or scale bar = 10 μM (zoom). All images are Z-projections of 6 optical sections taken at 2 μm distance.
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Figure 2 Glu uptake-induced reversal of glial GABA transporters contributes to tonic inhibition of neurons during enhanced network
activity. Left, holding currents from representative experiments plotted at 1 s intervals during control condition (black), SNAP-5114 application
(red) and washout (blue) with Gaussian fits to the histograms of the holding current recorded during each condition. Right, voltage clamp
recording segments (Vh = 0 mV) low-pass filtered at 1 kHz from the same experiments showed at left. (A) Effect of GAT-2/3 blockade by 100 μM
SNAP-5114 on the holding current in [Mg2+] = 1,800 μM buffer. (B) Effect of GAT-2/3 blockade by 100 μM SNAP-5114 on the holding current in
[Mg2+] = 10 μM buffer. (C) Effect of GAT-2/3 blockade by 100 μM SNAP-5114 on the holding current in [Mg2+] = 1 μM buffer in the presence of
the non-transportable Glu uptake blocker DHK (100 μM). Average holding current: 88.5 ± 26.4 pA in the presence of 100 μM DHK vs. 93.6 ± 27.2
pA in the presence of 100 μM DHK and 100 μM SNAP-5114, P = 0.31, N = 8 cells/5 animals. (D) Effect of GAT-2/3 blockade by 100 μM SNAP-
5114 on the holding current in [Mg2+] = 10 μM buffer in the presence of 100 μM picrotoxin. Average holding current: 9.3 ± 15.6 pA in control
vs. 7.5 ± 12.7 pA in the presence of 100 μM SNAP-5114, P = 0.58, N = 4 cells/2 animals.
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current: 74.9 ± 16.7 pA in control vs. 71.7 ± 17.1 pA in
the presence of 100 μM SNAP-5114, P = 0.40, N = 8
cells/7 animals).
To investigate whether Glu uptake induced glial GAT
reversal can occur under enhanced neuronal activity, we
applied reduced-[Mg2+] buffers to remove the Mg2+
blockade from NMDA receptors [34]. It is important to
differentiate these reduced-[Mg2+] buffers from the low-
[Mg2+] epilepsy model, used both in our lab [35] and by
other groups [36]. The conditions applied in these
experiments differ from seizure-generating conditions in
two essential terms: (1) extracellular [K+] was not ele-
vated in contrast to the slightly increased value (5 mM)
used in seizure generation [37] and (2) we used 300 μm
hippocampal slices in which the connectivity is less pre-
served than in the 400 μm slices usually utilized as an
epilepsy model [35]. As a consequence, recurrent sei-
zure-like events were observed in only 20% of the slices
exposed to the [Mg2+] = 1 μM or [Mg2+] = 10 μM
environment.
Application of [Mg2+] = 1 μM buffer resulted in a sig-
nificant increase in both frequency (21.4 ± 2.2 Hz in
control vs. 44.4 ± 2.5 Hz in reduced-[Mg2+], P < 0.001)
and amplitude (28.6 ± 1.6 pA in control vs. 55.9 ± 6.9
pA in reduced-[Mg2+], P < 0.001) of spontaneous IPSCs
(sIPSCs). Under these conditions, blockade of GAT-2/3
Figure 3 Glial GABA transporter mediated tonic inhibition correlates with network activity. (A) Box-chart representation of the average
holding currents from individual experiments during control condition, SNAP-5114 application and washout. Box edges represent 25th, 50th and
75th percentile, open squares represent means, circles connected by lines represent paired individual baseline values. Average holding current in
control: [Mg2+] = 1,800 μM: 78.9 ± 12.4 pA (N = 12 cells/2 animals); [Mg2+] = 100 μM: 63.0 ± 12.0 pA (N = 7 cells/3 animals); [Mg2+] = 30 μM:
155.0 ± 12.6 pA (N = 10 cells/3 animals); [Mg2+] = 10 μM: 121.2 ± 13.3 pA(N = 8 cells/4 animals); [Mg2+] = 1 μM: 88.8 ± 11.8 (N = 15 cells/9
animals); Bottom right: Average change in holding current in response to SNAP-5114 application as a function of the sIPSC frequency. Columns
represent the means of holding current changes from all experiments having sIPSC frequency in the given 5 Hz wide frequency range during
the control period. (B) Left: Holding currents during exogenous Glu application (100 μM, red) and washout (blue) in [Mg2+] = 10 μM buffer in
the presence of Glu receptor antagonists CNQX (10 μM) and DL-AP5 (50 μM). Average holding current: 66.2 ± 23.5 pA in control vs. 93.0 ± 27.2
pA in the presence of 100 μM Glu, P < 0.001, N = 15 cells/8 animals. Middle: Holding currents during exogenous Glu application (100 μM, red)
and washout (blue) in [Mg2+] = 10 μM buffer in the presence of Glu receptor antagonists CNQX (10 μM),DL-AP5 (50 μM) and (S)-MCPG (500 μM).
Average holding current: 54.3 ± 17.4 pA in control vs. 69.1 ± 17.1 pA in the presence of 100 μM Glu, P = 0.01, N = 5 cells/4 animals. Right:
Average change in holding current in response to increasing concentration (1 μM, 10 μM and 100 μM) of exogenous Glu in the presence of
CNQX (10 μM) and DL-AP5 (50 μM). Asterisks represent significant change in holding current (P < 0.05).
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transporters significantly suppressed the tonic inhibition
of CA1 pyramidal cells (Figures 2B and 3A), demon-
strating that, during enhanced excitation, GABA release
by reversal of GAT-2/3 significantly contributes to the
tonic inhibition of neurons. This behavior is in sharp
contrast to the direction of tonic current change we
would expect from a GABA transporter working in the
typical, outside-in direction, where the transporter
blockade would lead to increased GABAergic inhibition.
SNAP-5114 application during combination of reduced-
[Mg2+] condition with stimulation of Schaffer collaterals
resulted in similar reduction of the tonic current (aver-
age holding current: 68.8 ± 18.7 pA in control vs. 49.3 ±
15.5 pA in the presence of 100 μM SNAP-5114, P =
0.04, N = 8 cells/7 animals). It is worth noting that
neither the frequency (29.9 ± 1.5 Hz vs. 27.9 ± 1.4 Hz,
P = 0.31), nor the peak amplitude (38.9 ± 4.4 pA vs.
33.3 ± 3.0 pA, P = 0.24) of the sIPSCs changed signifi-
cantly during SNAP-5114 application compared to the
preceding period, excluding the possibility that the
decrease in the holding current is due to a change in
IPSC kinetics.
To confirm that the GAT-2/3 mediated GABA release
is directly evoked by Glu uptake, we investigated
whether the SNAP-5114 sensitive tonic current compo-
nent can be eliminated by blocking Glu transporters.
We specifically blocked the glial EAAT2, the dominant
Glu transporter subtype in the hippocampus [38]. If
GAT reversal was evoked by glial EAAT activity, block-
ade of EAAT2 should eliminate the SNAP-5114-sensi-
tive tonic current. On the contrary, if GABA release was
triggered by Glu receptor activation, the higher extracel-
lular Glu level due to EAAT blockade should result in
enhanced SNAP-5114 sensitive tonic current compo-
nent. In reduced-[Mg2+] buffer in the presence of the
specific, non-transportable EAAT2 inhibitor DHK (100
μM), application of SNAP-5114 had no effect on the
holding current (Figure 2C).
It is of note that the network activity in the presence
of DHK was not significantly different from the
reduced-[Mg2+] condition without DHK (frequency of
IPSCs: 38.8 ± 1.9 Hz without DHK vs. 35.9 ± 4.7 Hz
with DHK, P = 0.72), indicating that elimination of
GAT-2/3 mediated tonic current cannot be attributed to
desensitization of Glu receptors due to DHK blockade.
We also excluded the possibility that the observed
change in the holding current contributes to proteins
other than the GABAA receptor. In the presence of the
GABAA receptor antagonist picrotoxin (100 μM), block-
ade of GAT-2/3 by SNAP-5114 did not change the
holding current (Figure 2D), confirming that GABA
released from glial cells by GAT-2/3 reversal activates
GABAA receptors.
Taken together these data demonstrate that during
sustained excitation GABA released through GAT-2/3
in response to Glu transporter activation significantly
contributes to tonic inhibition of CA1 pyramidal cells.
GAT-2/3 mediated tonic component emerges gradually
with increasing network activity
To investigate whether the GAT-2/3 mediated tonic
component turns on beyond a threshold level or
emerges gradually in line with the increasing network
activity, we explored the effect of GAT-2/3 blockade on
tonic GABAergic currents in ACSF buffers with different
levels of extracellular [Mg2+]. Extracellular [Mg2+] was
varied in a wide range from the full blockade to the
total unblock of the NMDA receptors [34] (Figure 3A).
We showed that in the control buffer ([Mg2+] = 1,800
μM) there is no effect of GAT-2/3 blockade on the
baseline current (Figures 2A and 3A). Applying 100 μM
Mg2+ that is still sufficient to block the NMDA recep-
tors [34] also did not lead to GAT-2/3 reversal (Figure
3A). Partial unblock [34] of the NMDA receptors by 30
μM Mg2+, however, revealed the SNAP-5114-sensitive
component in the GABAergic tonic inhibition (Figure
3A). Further enhancement of the neuronal activity by
applying 10 μM Mg2+ or nominally Mg2+-free buffer
(based on the Mg2+ contamination of the Ca2+ salts, we
estimated the Mg2+ concentration of this buffer to be
approximately 1 μM) led to a robust increase in the
contribution of GAT-2/3 reversal to the tonic current
(Figure 3A).
To specifically measure the GABAergic tonic current,
we used CsMeSO3 based pipette solution at 0 mV hold-
ing potential, the reversal potential of Glu receptors.
Therefore, we could not simultaneously record excita-
tory postsynaptic potentials and use these values to cor-
relate network activity with the GAT-2/3 mediated tonic
current component. To circumvent this limitation, we
utilized the sIPSC frequency as readout of the network
activity. Although this rough estimation of the network
activity may not be ideal, the frequency of sIPSCs,
indeed, significantly increased in the reduced-[Mg2+]
ACSF (21.4 ± 2.2 Hz in control vs. 44.4 ± 2.5 Hz in
[Mg2+] = 10 μM, P < 0.001), suggesting the reliability of
this assumption. The GAT-2/3 mediated tonic compo-
nent as a function of the sIPSC frequency (Figure 3A,
bottom right) clearly shows that the tonic inhibition
offered by astrocytes is proportional to the network
activity.
Tonic inhibition can be increased by exogenous Glu
We also assessed the level of excitatory drive required to
induce the astrocytic GABA release by stimulating
EAAT activity with different concentrations of
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exogenous Glu. Hippocampal slices were superfused
with [Mg2+] = 10 μM buffer. Fifteen minutes prior to
Glu application, the AMPA and NMDA receptors were
blocked by antagonists CNQX (10 μM) and DL-AP5 (50
μM), respectively. Under these conditions, application of
1 μM Glu did not change the tonic GABAergic current
(Figure 3B, right). However, 10 μM Glu significantly
increased the tonic inhibitory current (Figure 3B, right)
without altering the synaptic sIPSC parameters (27.1 ±
2.3 Hz in control vs. 27.8 ± 2.3 Hz in the presence of 10
μM Glu, P = 0.81). Further increase of the tonic inhibi-
tion was observed in the presence of 100 μM Glu (Fig-
ure 3B, left). The unaffected sIPSC parameters indicate
that most of the receptor-mediated actions of Glu were
indeed blocked by the applied antagonists. This was
further confirmed by the addition of the broad spectrum
metabotropic Glu receptor antagonist (S)-MCPG to the
buffer. 100 μM Glu was still able to significantly
increase the holding current in the presence of 10 μM
CNQX, 50 μM DL-AP5 and 500 μM (S)-MCPG (Figure
3B, middle). Although the increase in the holding cur-
rent was slightly smaller in the presence of the metabo-
tropic Glu receptor antagonist (S)-MCPG, suggesting
the involvement of glutamatergic activation of GABAer-
gic interneurons, the majority of the tonic inhibition
increase is clearly attributed to Glu transporter activa-
tion. Additionally, blockade of the GABA release by the
EAAT2-specific inhibitor DHK (Figure 2C) also sup-
ports the notion that Glu receptors do not considerably
contribute to the increase in tonic inhibition, since any
Glu receptor-mediated effect should have been intensi-
fied when Glu uptake was blocked. Altogether, these
data demonstrate that GABA release from astrocytes
can be directly evoked by physiologically relevant con-
centration of Glu through the activation of glial Glu
transporters.
It is worth noting that under control conditions ([Mg2
+] = 1,800 μM) we did not observe the enhancement of
tonic inhibition following application of Glu up to 100
μM either in the presence or in the absence of Glu
receptor antagonists CNQX (10 μM) and DL-AP5 (50
μM) with and without tetrodotoxin (1 μM), suggesting
that the preceding enhanced activity is a prerequisite for
the emergence of the Glu/GABA exchange process.
Glu uptake and GABA release are coupled by changes in
intracellular Na+ level
Next we addressed how the Glu transporter activity can
lead to GAT reversal. Both Glu and GABA transport
gain their driving forces from the concentration gradient
of Na+ between intracellular and extracellular compart-
ments [39]. The co-expression of EAAT2 and GAT-3
(Figure 1) raised the possibility that they share a com-
mon Na+ pool; therefore, the activity of EAAT2 may
directly affect the driving force of GAT-3. To investigate
whether changes in intracellular Na+ level is coupled to
the Glu-evoked GABA release, we monitored the intra-
cellular [Na+] in astrocytes in the CA1 str. radiatum and
str. pyramidale of rat hippocampal slices. The dye sul-
forhodamine 101 (SR101) was used to mark EAAT
expressing protoplasmic astrocytes [40] (Figure 4A) that
express Glu transporters but not Glu receptors [41].
The glial [Na+] was monitored using the Na+ ion-sensi-
tive dye SBFI.
Under control conditions ([Mg2+] = 1,800 μM), appli-
cation of SNAP-5114 (100 μM) decreased the glial [Na
+], indicating that the glial GATs are taking up GABA
and Na+ (Figure 4B, left). Contrary, activation of the
glial EAATs by the substrate t-PDC (200 μM) produced
a significant increase of intracellular [Na+] as the result
of an inward EAAT flux (Figure 4B, left). Subsequent
blockade of the GAT-2/3 transporters by SNAP-5114 in
the presence of t-PDC further increased the intracellular
[Na+] (Figure 4B, left) indicating that GABA transpor-
ters work in the reversed mode following EAAT activa-
tion. Comparing these results with the
electrophysiological measurements in ACSF on the
GAT-2/3 mediated tonic current component in
response to SNAP-5114 (Figure 2) and exogenous Glu
suggest that although GABA can be released by the
Glu/GABA exchange mechanism under control condi-
tions as well, its amount is most probably not sufficient
to activate the extrasynaptic GABAA receptors.
When the network activity was intensified using the
[Mg2+] = 10 μM buffer, SNAP-5114 alone was able to
increase the glial [Na+] (Figure 4B, right), indicating that
glial GATs are reversed even without activating the
EAATs by exogenously applied substrate in accordance
with the electrophysiological results (Figure 2B). Further
triggering the Glu/GABA exchange mechanism by 200
μM t-PDC resulted in a largely enhanced reverse uptake
capacity for GAT-2/3 as indicated by the increased
response to SNAP-5114 (Figure 4B, right).
It is worth emphasizing that the magnitude of the glial
[Na+] changes in this experiment (Figure 4) underesti-
mates the concentration changes in the vicinity of the
transporters because the values were measured in the
soma, far from the end feet where the most significant
changes occur. As an example for [Na+] changes in a
domain with the size comparable to the end feet of
astrocytes, intracellular [Na+] may rise up to 100 mM in
active dendritic spines of CA1 neurons [42].
Alternative metabolic pathway provides releasable GABA
in astrocytes
Electrophysiological studies outlined above clearly
showed GAT-2/3 mediated GABA release from astro-
cytes. The source of glial GABA, however, remained
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undecided. GABA is synthesized mainly from Glu by the
enzyme Glu decarboxylase. The majority of this pathway
takes place in neuronal cells [43]; therefore, it is widely
believed that astrocytes do not contain significant
amounts of GABA. There is, however, an alternative
metabolic pathway to GABA. The polyamine putrescine
can be converted to GABA by monoamine oxidase [44]
in neurons and glial cells as well [45]. Several lines of
evidence suggest that this alternative pathway might
play a neuroprotective role in multiple models of epi-
lepsy [46-48]. We previously demonstrated by NMR
measurements that Glu-induced GABA release is,
indeed, independent of Glu decarboxylase [24]. There-
fore, we sought to assess whether GABA synthesized
from putrescine in glial cells may be the source of the
release. Unfortunately, 13C or 14C labelled putrescine is
unavailable currently. Consequently, we could not
directly test whether the released GABA originates from
putrescine.
Instead, we first opted to evaluate the potential of the
putrescine-GABA pathway to produce significant
amount of GABA by estimating the changes in the
intracellular and extracellular concentrations of GABA
and putrescine in the reduced-[Mg2+] environment.
Since the ornithine-putrescine conversion represents the
rate-limiting step in the polyamine synthesis [43], we
also monitored the concentration of the putrescine pre-
cursor ornithine. Hippocampal slices were incubated in
normal ACSF and in [Mg2+] = 1 μM ACSF for one
hour. Following the incubation, the bathing solutions
were removed and used to assess the extracellular con-
centrations. The slices were subject to a mild digestion
procedure (see Methods) that is expected to selectively
extract GABA from the cytosolic compartment and
Figure 4 Changes in glial [Na+] in response to EAAT activation and GAT-2/3 blockade. (A) Confocal imaging reconstruction of
protoplasmic astrocytes marked by sulforhodamine 101 (SR101) in the hippocampal CA1 region. R: str. radiatum, P: str. pyramidale, O: str. oriens.
Scale bar = 50 μm. (B) Intracellular [Na+] in the soma of SR101 identified astrocytes measured by SBFI fluorescence during 100 μM SNAP-5114
applications with (black line) or without (red line) preceding activation of the Glu transporters by 200 μM t-PDC in normal ACSF (left) and [Mg2+]
= 10 μM ACSF (right). Average of N = 16 cells/2 animals (normal ACSF) and N = 29 cells/3 animals ([Mg2+] = 10 μM).
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leave the vesicular stores intact. The digestion products
were used to estimate the cytosolic concentrations. The
putrescine, ornithine and GABA concentrations in both
the slice extracts and the bathing solutions were deter-
mined by mass spectrometry. Under control conditions,
cytosolic putrescine concentration was found to be 21.8
± 1.6 pmol/mg wet tissue, while extracellular putrescine
was measured as 12.2 ± 0.9 pmol/mg wet tissue, both in
good agreement with data from other groups [49-51].
GABA concentration was calculated as approximately 1
mM in the cytosolic compartment and approximately
0.7 μM in the extracellular space, both in good agree-
ment with previous values [52,53]. Although the abso-
lute concentrations should be treated with considerable
care due to the indirect sampling protocol, they suggest
that we indeed sampled the appropriate pools.
We found that putrescine and ornithine concentra-
tions were significantly decreased in the cytosolic pool
(Figure 5A) in the reduced-[Mg2+] environment.
Ornithine concentration was also decreased in the extra-
cellular space when exposed to the reduced-[Mg2+]
ACSF (Figure 5A). These data demonstrate the
increased metabolic conversion of ornithine and putres-
cine. Cytosolic GABA concentration was also signifi-
cantly decreased compared to the control condition.
However, a remarkable increase was observed in the
bath concentration of GABA (Figure 5A) in accordance
with the tonic inhibition measurements (Figure 2). The
increase in the bath concentration of GABA and the
decrease in cytosolic [GABA] were both completely
blocked by 100 μM SNAP-5114 (Figure 5B), demon-
strating that GABA release was indeed mediated by
GAT-2/3 transporters. When SNAP-5114 was present
in the reduced-[Mg2+] buffer, both cytosolic and bath
[putrescine] were increased (Figure 5B), suggesting that
maintenance of the putrescine-GABA conversion
requires the continual removal of the synthesized
GABA. In the absence of GABA efflux the ornithine-
derived putrescine is released to the extracellular space
by the depolarization-induced polyamine secretory path-
way [54,55]. The marked difference in the putrescine
concentrations in the absence and presence of SNAP-
5114 also signifies the correlation between the putres-
cine-GABA pathway and GAT-2/3 activity.
To confirm the contribution of the putrescine-derived
glial GABA to the tonic inhibition of neurons, we inves-
tigated the tonic GABAergic currents under blockade of
the putrescine-GABA metabolic pathway using the
monoamino oxidase inhibitor deprenyl in combination
with the diamine oxidase inhibitor aminoguanidine [44].
In the [Mg2+] = 1 μM buffer that was used to investigate
the Glu-induced GABAergic currents, the presence of 10
μM deprenyl and 100 μM aminoguanidine eliminated
the GAT-2/3 mediated tonic current component (Figure
5C).
Furthermore, the involvement of the putrescine-GABA
pathway as the source of releasable glial GABA was also
confirmed by measuring the glial [Na+] changes in
response to the EAAT substrate t-PDC (200 μM) and
the GAT blocker SNAP-5114 (100 μM) (Figure 5D) in
the presence of 10 μM deprenyl and 100 μM aminogua-
nidine. Activation of the Glu transporters by t-PDC
resulted in increased glial [Na+], however, this value
could not be further increased by SNAP-5114 during
either control conditions or enhanced network activity,
suggesting that the releasable glial GABA is missing
when the putrescine-GABA pathway is blocked (cf. Fig-
ure 4C). It is worth noting that the magnitude of the
glial [Na+] increase in response to t-PDC in the pre-
sence of deprenyl and aminoguanidine (Figure 5D) was
comparable to that measured in the presence of SNAP-
5114 when the putrescine-GABA pathway was intact
(Figure 4B), indicating that this [Na+] increase can be
achieved when the GAT-2/3 transporters are not releas-
ing the Na+ to the extracellular space.
These data suggest that the putrescine-GABA meta-
bolic pathway emerges during enhanced network activity
and provides the glial GABA that contributes to the
tonic inhibition of neurons.
Glu uptake-induced GABA release from astrocytes
reduces the duration of seizure-like events
Since the Glu uptake-induced GABA release correlates
with the network activity and the metabolic pathway
yielding the glial GABA is also known to be induced
during enhanced activity [48], it is reasonable to expect
that the tonic current provided by astrocytes combats
overexcitation in pathophysiological states characterized
by sustained, enhanced network activity, such as epi-
lepsy. To evaluate this possibility, we exposed freshly
isolated, 400 μm entorhinal-hippocampal slices from
P11-13 rats to nominally Mg2+-free ACSF with slightly
elevated (5 mM) extracellular [K+]. In the low-[Mg2+]
model of epilepsy [35-37], 73% of slices generated recur-
rent seizure-like events (SLEs) within 20 minutes from
the exposure to low-[Mg2+]/elevated-[K+] ACSF. Follow-
ing the appearance of at least two fully developed SLEs,
we applied 100 μM SNAP-5114 to block the GAT-2/3
mediated tonic current component (Figure 6A-C). The
effects of SNAP-5114 on the SLEs were quantified by
measuring the total duration of the SLEs, the duration
of the tonic- and clonic-like periods, the interval
between two consecutive SLEs and the intensity of the
SLEs (see Methods). Total duration of SLEs significantly
increased from 119.9 ± 8.9 s (control) to 161.4 ± 13.6 s
when the GAT-2/3 mediated tonic current component
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was blocked by SNAP-5114 (Figure 6D, P = 0.006, N =
13 slices/5 animals). The increase in duration specifically
affected the clonic-like period (Figure 6E, 72.2 ± 7.3 s in
control vs. 114.2 ± 13.2 s during SNAP-5114 applica-
tion, P = 0.007), leaving the duration of the tonic-like
period intact (Figure 6E, 49.3 ± 3.1 s in control vs. 49.9
± 3.0 s during SNAP-5114 application, P = 0.84). The
interval between SLEs and the SLE intensity were also
unaffected by SNAP-5114 application (Figure 6F, G).
The Glu/GABA exchange mechanism modulates
electrophysiological properties under physiological
conditions in vivo
By monitoring the glial [Na+] to determine whether glial
GATs work in the normal or the reversed mode, we
demonstrated that GAT-2/3 can be reversed by activat-
ing the glial Glu transporters under physiological condi-
tions (Figure 4). However, the amount of the released
GABA is most probably not sufficient to activate the
Figure 5 GABA released from astrocytes is synthesized from putrescine. (A-B) Concentration of ornithine, putrescine and GABA in
hippocampal slice tissues and in the bathing medium following one hour incubation normal ACSF (control) or in [Mg2+] = 1 μM ACSF in the
absence (A) and presence (B) of 100 μM SNAP-5114 as determined by LC-MS. Asterisks represent significant change (P < 0.05). (C) Holding currents
in [Mg2+] = 1 μM buffer in the presence of the monoamino oxidase inhibitor, deprenyl (10 μM) and the diamino oxidase inhibitor, aminoguanidine
(100 μM). Left, baseline currents plotted at 1 s intervals during control condition (black), SNAP-5114 application (red) and washout (blue); right, box-
chart representation of GABAergic baselines during control condition, SNAP-5114 application and washout. Box edges represent 25th, 50th and 75th
percentile, open squares represent means, circles connected by lines represent paired individual baseline values. Average holding current in
control: 74.8 ± 12.8 (N = 8 cells/6 animals). (D) Intracellular [Na+] in the soma of SR101 identified astrocytes measured by SBFI fluorescence during
100 μM SNAP-5114 applications with (black line) or without (red line) preceding activation of the Glu transporters by 200 μM t-PDC in [Mg2+] = 10
μM ACSF in the presence of deprenyl (10 μM) and aminoguanidine (100 μM) (average of N = 13 cells/2 animals).
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extracellular GABAA receptors (Figure 2A). In vitro, the
GABA provided by astrocytes can contribute to the
tonic inhibition only when network activity is
considerably enhanced. The network activity in an in
vitro brain slice preparation, however, is inherently
reduced compared to the in vivo intact brain [56]. To
Figure 6 Blockade of GAT-2/3 mediated tonic inhibition increase the duration of seizure-like events. (A) Representative field potential
recording of seizure-like events (SLEs) from the CA3 pyramidal layer of a hippocampal slice from a P11 rat. Bar shows SNAP-5114 (100 μM)
application. (B-C) Comparison of SLEs (boxed in A) occurred during control condition (B) and SNAP-5114 application (C). (D-G) Average duration
of SLEs (D), average duration of tonic- and clonic-like periods (E), average inter-SLE intervals (F) and average SLE intensity (G) from 13 slices
exhibiting recurrent SLEs. Asterisks represent significant change compared to the control (P < 0.05), ns means not significant.
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explore whether the Glu/GABA exchange mechanism
can provide significant contribution to inhibitory actions
in vivo under physiological conditions, we studied the
effect of t-PDC and SNAP-5114 on the gamma range
oscillation in the CA1 region of rats under ketamine/
xylazine anesthesia.
The CA3 and CA1 gamma range (30 to 80 Hz) oscil-
lations are hypothesized to share similar neuronal
mechanisms under in vivo and in vitro conditions
[57-59]. It is also well known that the hippocampal inhi-
bitory neural network plays an important role in the
gamma range oscillation [60]. It was also shown that
gamma oscillation is coordinated by the intricate inter-
play between pyramidal cells and interneurons mostly
by a dominant GABAergic inhibitory input on pyramidal
cells [61]. Importantly, under ketamine/xylazine anesthe-
sia the CA1 region exhibits gamma range burst activity
comparable to that during memory task performance
[57], albeit in the low gamma range (30 to 50 Hz).
Topical injection (N = 3) of the EAAT substrate t-
PDC (1 mM) to the str. radiatum of the CA1 (Figure
7A) resulted in the power increase of the current source
density (CSD) in this region in the frequency range
peaking around 31-35 Hz. This effect lasted for about
four to eight minutes. Representative FFT power
changes after t-PDC injection compared to the pre-
injection period showed significant (P < 0.005) increase
in the power of the gamma oscillation (Figure 7B). In
contrast, t-PDC injected with 1 mM SNAP-5114 (N =
3) evoked a power suppression at gamma peak (Figure
7C). This suppression was also statistically significant in
all injections in the CA1 str. radiatum, measured by the
CSD FFT power spectrum. Injection of 1% dimethyl
sulfoxide (DMSO) in saline solution (N = 3) that is used
to dilute SNAP-5114 (and also added to the t-PDC solu-
tion to make the results strictly comparable) did not
change the gamma power (P > 0.05) in the CA1 str.
radiatum (Figure 7D).
Discussion
The experiments in this paper establish, for the first
time, a direct conversion of glutamatergic excitation to
GABAergic inhibition by astrocytes. We showed that
during enhanced network activity a previously unrecog-
nized inhibitory mechanism emerges, by which the
uptake of Glu is coupled to the subsequent reversal of
Figure 7 Effect of t-PDC and SNAP-5114 on the gamma band activity in the CA1 region of rats under ketamine/xylazine anaesthesia.
(A) Left: Nissl stained section of the injector electrode penetration track. The vertical black line represents the track. Scale bar is 1 mm. Right:
single sweep CSD activity from the str. pyramidale to the thalamus during high amplitude gamma activity in the hippocampus. Injection site
was located between CSD channel 4 and 5. CSD values are in arbitrary units, time and amplitude calibration is 300 ms and 1024 μV respectively.
(B) Effect of t-PDC (1 mM) on the CA1 str. radiatum CSD power compared to the pre-injection control. Black line with asterisk marks significant
(P < 0.005) CSD power increase after t-PDC application. Power is normalized to the peak power of the control in the gamma (30 to 80 Hz)
range. (C) Effect of simultaneous application of t-PDC (1 mM) and SNAP-5114 (1 mM) mixture on the CA1 str. radiatum CSD power compared to
the pre-injection control. Black line with asterisk marks significant (P < 0.005) CSD power drop after t-PDC and SNAP-5114 application. (D) Effect
of the saline solution containing 1% DMSO on the CA1 str. radiatum CSD power compared to the pre-injection control. No significant CSD
power change was detected in the gamma range.
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the glial GABA transporters bringing about an elevation
in the level of extracellular GABA and increasing the
tonic inhibition of neurons. The presence of this Glu/
GABA exchange mechanism was demonstrated by mea-
suring the GAT-2/3 mediated tonic inhibitory current
component of CA1 pyramidal cells and by monitoring
the glial [Na+] under the blockade of glial Glu and
GABA transporters in reduced-[Mg2+] conditions. We
identified the polyamine putrescine as the source of the
releasable glial GABA. Additionally, we revealed that the
level of tonic inhibition provided by astrocytes is directly
proportional to the network activity resulting in a tune-
able, in situ negative feedback, which in turn counterba-
lances the excitation during recurrent seizure-like events
in an in vitro epilepsy model. Furthermore, we provided
evidence that the Glu uptake-induced glial GABA
release occurs under physiological conditions in vivo,
showing that increasing the extrasynaptic GABAergic
signalling by triggering the Glu/GABA exchange
mechanism results in the modulation of gamma oscilla-
tion power.
Proposed model of Glu induced GABA release
To explain the current findings, we propose a model for
the mechanism underlying extracellular Glu/GABA
exchange by astrocytes (Figure 8). Importantly, we showed
that the GAT-2/3 mediated tonic current component can
be diminished by blocking glial Glu transporters (Figure
2C), demonstrating that GAT reversal is evoked directly
by Glu uptake. Removal of Glu from the extracellular
space is coupled [39] to co-transport of 3 Na+/1 H+ and
counter-transport of 1 K+, resulting in subsequent disrup-
tion of the resting electrochemical potential. Because
GABA transport is also driven by the Na+ gradient, the
increased intracellular [Na+] may be capable of reversing
GABA transporters. Both theoretical and experimental
studies suggest that GABA transporters operate close to
their equilibrium potential [18,62,63]; therefore, even
small changes in the concentration of the underlying sub-
strates (Na+, Cl- or GABA) may initiate the reversed
mode. Indeed, we found that activation of Glu transporters
significantly increases the intracellular [Na+] even in the
soma of astrocytes (Figure 4). Following EAAT activation,
blockade of GAT-2/3 further elevates glial [Na+] demon-
strating that glial GABA transporters are reversed. Impor-
tantly, the [Na+] changes in the local environment of the
transporters are expected to be more substantial. Taking
into account the presence of GAT-2/3 on astrocytic end
feet ensheathing glutamatergic synapses [25,26] and the
colocalization of EAAT2 and GAT-2/3 (Figure 1), the glial
Glu and GABA transporters may share a common domain
in the astrocytic end feet. Therefore, the Na+ influx
through EAATs may robustly change the driving force of
GATs and can lead to transporter reversal.
According to our model, the released GABA activates
the extrasynaptic GABA receptors and contributes to the
tonic inhibition of neurons. This transporter-mediated
molecular interplay represents a direct link between inhi-
bitory and excitatory neurotransmission and functions as
an adjustable negative feedback that may combat intense
excitation in epilepsy. Indeed, we found that in the low-
[Mg2+] model of epilepsy, blockade of the GABA release
through GAT-2/3 transporters significantly increases the
duration of seizure-like events (Figure 6), signifying the
role of Glu/GABA exchange process in neuroprotection.
Moreover, beyond the primary benefit of turning excita-
tion into inhibition, the Glu/GABA exchange also contri-
butes to the recovery of the transmembrane Na+ gradient
without using ATP thereby saving energy while protect-
ing the neurons. Our in vivo findings of increased power
in the gamma range due to t-PDC application and its
elimination by SNAP-5114 also strengthen the hypothesis
that Glu induced GABA release can play an important
role in the hippocampal excitability.
Occurrence of the Glu/GABA exchange mechanism under
in vitro conditions
It is an important issue under what circumstances the
Glu/GABA exchange appears. Under in vitro conditions
Figure 8 Schematic representation of the mechanism
underlying Glu/GABA exchange. GAT-2/3 transporters are
expressed on glial end feet surrounding glutamatergic synapses and
colocalize with EAAT2 transporters. Glial uptake of Glu is coupled to
the release of GABA by a mechanism through which Na+ that is
cotransported with Glu drive the release of GABA synthesized from
putrescine. The released GABA contributes to tonic inhibition of
neurons.
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we observed GAT-2/3 mediated tonic current compo-
nent only in low-[Mg2+] environment. Although glial
[Na+] measurements suggest that the GAT-2/3 trans-
porters can be reversed by activation of the Glu trans-
porters under normal, physiological activity (Figure 4B,
left), blockade of GAT-2/3 did not change the tonic
inhibition of CA1 pyramidal neurons (Figure 2A) under
the same conditions. The apparent discrepancy between
the measurements of glial [Na+] level and of tonic inhi-
bition may denote that the GABA released through
GAT-2/3 is either taken up before reaching the extracel-
lular GABAA receptors or its concentration is not suffi-
cient to activate them. Since GAT-2/3 are localized on
glial processes facing the extrasynaptic space [25,26]
where the GABAA receptors responsible for the tonic
inhibition reside [64], the synaptically localized GAT-1
transporters cannot take up the released GABA. There-
fore, having no major route to remove GABA from the
extrasynaptic space, it is more likely that under control
conditions the released amount of GABA is not suffi-
cient to activate extrasynaptic GABAA receptors.
Enhancing the network activity by lowering the extra-
cellular [Mg2+] turns on the Glu/GABA exchange pro-
cess as monitored by both glial [Na+] measurements
(Figure 4B, right) and GABAergic tonic inhibition (Fig-
ures 2B and 3A). Lowered [Mg2+] and increased net-
work activity may lead to diverse physiological actions.
As some examples, low Mg2+ level can open up TRPM7
channels resulting in Na+ influx [65] and subsequent
depolarization of neurons. The increased network activ-
ity can also initiate overexpression of glial Glu and
GABA transporters [66-68] that may enhance the mag-
nitude of the Glu/GABA exchange process. Moreover,
reversal of glial GABA transporters can also be facili-
tated by increased glial GABA production in response
to the elevated extracellular [Glu] [69].
Glial GABA production can also be enhanced by
activation of the putrescine-GABA pathway. Although
the source of glial GABA is poorly understood, it has
been demonstrated that GABA is indeed available in
astrocytes [70-72]. Apart from the major source of
GABA (forming from Glu by glutamate decarboxylase
in neurons), an alternative pathway does exist in the
brain by which GABA is formed by monoacetylation of
the polyamine putrescine in both neurons and glial
cells [73]. Although the capacity of this pathway is
modest, it can produce detectable levels of GABA in
astrocytes [74]. Importantly, this pool of GABA is
inducible. The formation of GABA from putrescine is
markedly increased in the epileptic mouse strain DBA/
2J [48]. Also, long-lasting increase in putrescine level
was demonstrated following kainate-induced seizure
activity in rat brain in vivo, particularly in the hippo-
campus [46]. Moreover, putrescine production can also
be induced by glutamine [75]; therefore, it can be
directly coupled to the uptake of Glu that is converted
to glutamine by astrocytes. The activity induced forma-
tion of GABA from putrescine, therefore, is a good
candidate to explain the source of the released GABA
and may also enlighten why putrescine overproduction
offers neuroprotection by significantly increasing sei-
zure threshold [47].
In conclusion, among the various physiological
changes in response to the low-[Mg2+] environment, we
consider the activity-induced enhancement of the
putrescine-GABA synthetic pathway as the major deter-
minant of the appearance of the Glu/GABA exchange
mechanism, because its blockade eliminated the GAT-2/
3 mediated component of both the tonic inhibition (Fig-
ure 5B) and the glial [Na+] increase (Figure 5C).
Occurrence of the Glu/GABA exchange mechanism under
in vivo conditions
Either the activation of the putrescine-GABA pathway
or some other mechanisms underlie the emergence of
the Glu/GABA exchange, the GAT-2/3 mediated tonic
inhibitory component could only be detected during
intensified network activity under low-[Mg2+] conditions
in vitro. The network activity in an in vitro brain slice
preparation, however, is inherently reduced when com-
pared to the in vivo intact brain [56]. It is, therefore, fea-
sible that the intrinsically higher in vivo network activity
may provide sufficient drive to trigger the Glu/GABA
exchange mechanism. Indeed, the gamma range oscilla-
tion that is known to be coupled to the GABAergic inhi-
bitory input on pyramidal cells [61] has been modulated
by the Glu transporter substrate under in vivo physiolo-
gical conditions. Although the application of a Glu
transporter substrate/inhibitor may affect the network
dynamics in several different ways, it is important that
the modulatory effect of t-PDC could be fully reversed
by SNAP-5114. If the gamma power increase was pro-
duced by a rise in the extracellular Glu in response to t-
PDC application, the resulting excitation cannot be
eliminated by the blockade of the glial GABA transpor-
ters that are working in the standard, outside-in direc-
tion, due to the minor contribution of GAT-2/3 to the
total GABA uptake capacity. The inversion of the t-PDC
induced gamma power modulation by SNAP-5114,
therefore, suggests that they are acting on different tar-
gets of the same mechanism.
Potential therapeutic implications
The magnitude of tonic inhibition provided by glial Glu/
GABA exchange is proportional to the degree of net-
work activity, thus it is more prominent in excited
states. From the pharmacological point of view, treat-
ments that target a mechanism up-regulated in situ in
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pathological conditions may represent an ideal strategy
for drug development.
The coupling between substrate activation of EAATs
and subsequent GABA release can well explain some
previous observations. The mechanism implies that
transportable and non-transportable inhibitors of Glu
uptake should have differential effects on neuronal viabi-
lity. Indeed, this distinction was observed in several
cases. In contrast to the non-transportable blocker
DHK, the substrate t-PDC did not evoke neuronal
damage in vivo even in very high concentrations (25 to
100 mM), despite the fact that extracellular [Glu] eleva-
tion was similar [76] or even higher [77] after t-PDC
application than following DHK treatment. Also, in vivo
administration of TBOA in the hippocampus was
demonstrated to induce neuronal damage in the CA1
and the dentate gyrus, while t-PDC application did not
produce cell death [78].
Overexpression of glial Glu and GABA transporters
may significantly increase the magnitude of the Glu-
induced GABA release by increasing both the Na+ influx
through EAATs and the amount of GABA released
through GATs. The antiepileptic drugs clobazam and
levetiracetam have been shown to up-regulate GAT-3
expression in the hippocampus [66,67]. The marked
increase of GAT-3 expression in astrocytes was also
demonstrated in the hippocampi of patients with tem-
poral lobe epilepsy [68]. The dysfunction of the mechan-
ism may also lie behind the impairment of the cross-talk
between excitatory and inhibitory transport processes in
temporal lobe epilepsy [79].
Conclusions
This study, together with our previous work, demon-
strates the existence of a previously unrecognized adap-
tive neuroprotective mechanism, by which astrocytes
offer an in situ, tuneable negative feedback on neurons.
In acute hippocampal slices, the mechanism can be
observed only during enhanced network activity evoked
by low-[Mg2+] condition. However, occurrence of the
Glu/GABA exchange mechanism in vivo suggests that
the Glu/GABA exchange can be operational under phy-
siological conditions in the intact brain. We envision
that the discovery of the conversion of glutamatergic
excitation to tonic inhibition will deepen our under-
standing of how physiological network activity can be
regulated in the brain and may open up new possibilities
for the treatments of pathological conditions, such as
epilepsy or ischemia.
Methods
Animals were kept and used in accordance with the
European Council Directive of 24 November 1986 (86/
609/EEC) and the Hungarian Animal Act, 1998 and
associated local guidelines. All efforts were made to
reduce animal suffering and the number of animals
used.
Buffers
Buffers contained in mM ACSF: 129 NaCl, 3 KCl, 1.6
CaCl2, 1.8 MgSO4, 1.25 NaH2PO4, 21 NaHCO3, 10 glu-
cose (pH 7.4); nominally Mg2+-free ACSF was prepared
as control ACSF with no added Mg2+ (based on the
Mg2+ contamination of the Ca2+ salts, we estimated the
Mg2+ concentration of this buffer to be approximately 1
μM).
Slice preparation
Transverse, 300 μm thick hippocampal-entorhinal slices
from 10- to 18-day-old Wistar rats (Toxicoop, Budapest,
Hungary) were prepared in modified ACSF (75 mM
sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM
NaH2PO4, 7 mM MgSO4, 0.5 mM CaCl2, 25 mM
NaHCO3, 25 mM glucose, continuously bubbled with
95% O2 + 5% CO2 gas mixture) at 4°C, as described
before [80]. In most of the experiments (158 out of
163), animals between P11-15 were used, while in mea-
surements of recurrent seizure like activity (SLE) the
age range was further reduced to P11-13 since they are
more susceptible to developing seizures [35,80]. Slices
were incubated in an interface-type chamber that was
continuously circulated with ACSF for one hour at 37°C
(followed by incubation at room temperature) before
performing the experiments. In lowered [Mg2+] experi-
ments slices were incubated in ACSF containing
approximately 100 μM. In experiments where the dia-
mine oxidase inhibitor, aminoguanidine, was applied,
aminoguanidine was added to the ACSF before incubat-
ing the slices in the interface chamber in order to effec-
tively block the putrescine-GABA synthetic route.
In vitro electrophysiology
Electrophysiological recordings were performed either at
room temperature or at 31°C. Signals were recorded
with Multiclamp700A amplifiers (Axon Instruments,
Foster City, CA, USA), low-pass filtered at 2 kHz and
digitized at 10 kHz (Digidata1320A, Axon Instruments).
For single cell recording CA1 pyramidal cells were iden-
tified visually. Pipettes (5 to 9 MΩ) were filled with a
solution containing (in mM) 130 CsMeSO3, 10 NaCl,
0.05 CaCl2, 2 ATP (magnesium salt), 1 EGTA and 10
HEPES (pH set to 7.3 with 1N CsOH). To suppress
escape action currents 5 mM QX 314 (Tocris, Bristol,
UK) was added. Cells were voltage-clamped at 0 mV
(corrected for a calculated junction potential of +15
mV) to record GABAergic (outward) currents. Input
resistance was 171 ± 65 MΩ. If signs of seal deteriora-
tion or cell closure occurred (> 20% change in the
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access resistance) the recordings were discarded. Synap-
tic recordings were made for 10 to 25 minutes in con-
trol conditions following 10 to 20 minutes of 100
μMSNAP-5114 application and 10 to 30 minutes
washout.
In experiments where local Glu release at CA1 pyra-
midal cells was evoked, 100 μs, 500 μA stimuli were
applied to the Schaffer collaterals by a bipolar Tungsten
electrode at 15 s intervals. Experiments were discarded
if stimulation of Schaffer collaterals did not evoke
Gluergic current in the CA1 pyramidal cell voltage
clamped at -45 mV. Sweeps were recorded for 9 s fol-
lowing the stimulus and the ranges between 1.5 to 8 s
were used to analyze spontaneous IPSCs and to deter-
mine the baseline in order to exclude evoked responses.
Synaptic currents were identified as GABAergic inhibi-
tory postsynaptic currents and baseline currents were
validated as a measure of tonic GABAergic currents by
adding the GABAA antagonist picrotoxin (100 μM) at
the end of 43 of 154 experiments (Figure 9). Picrotoxin
sensitive tonic current was found to be 53.1 ± 10.7 pA,
57.1 ± 8.4 pA and 63.4 ± 10.7 pA at [Mg2+] = 1, 10 and
30 μM, respectively.
Holding currents were determined according to Gly-
kys et al. [81]. All-point histograms were plotted for
each sweep (in episodic recording mode when the
Schaffer collaterals were stimulated) or for each 20 s
period of experimental traces (in gap-free recording
mode). A Gaussian was fitted to the unskewed part of
the histogram and the position of the center of the fitted
Gaussian was used as the holding current. Values during
SLEs were not included in data evaluation. Experiments
were discarded if the holding current continuously
shifted to either a negative or positive direction during
both SNAP-5114 or Glu application and washout,
except when the shift was clearly linear, in which case
the holding current values were detrended. Spontaneous
IPSCs were analyzed by the MiniAnalysis software
(Synaptosoft, Decatur, GA, USA) using 10 pA as
amplitude threshold. sIPSCs with event frequency values
greater than 300 Hz were excluded from histogram
plots to avoid duplicate sIPSC detection.
Epileptiform activity was induced in 400 μm thick hip-
pocampal slices by switching the perfusing solution to
ACSF with no added Mg2+ ions and [K+] raised to 5
mM. Field potential recordings were performed with
glass microelectrodes (3 to 5 MΩ) inserted into the
CA3 stratum pyramidale. Slices were discarded if SLE
did not appear in 20 minutes starting from the exposure
to low-[Mg2+]/elevated-[K+] ACSF. Being not fully
developed, the first SLEs were always discarded from
data evaluation. Recordings were analyzed after high-
pass filtering at 1 Hz. Tonic-to-clonic transitions were
identified by the first reappearance of secondary dis-
charges. SLE intensity was calculated as the standard
deviation (SD) of the field potential trace containing the
whole SLE, normalized to the SD of the preceding
period.
In vivo electrophysiology
Rats (N = 6) weighing 250 to 350 g were used for the in
vivo experiments. All procedures followed NIH Guide-
lines for the Use of Laboratory Animals. In each animal,
pressure injections of saline (0.9% w/v) + DMSO (1%),
t-PDC (1 mM, in saline containing 1% DMSO) and t-
PDC (1 mM) + SNAP-5114 (1 mM) (in saline contain-
ing 1% DMSO) were made into the CA1 area of the hip-
pocampus, in approximate stereotactic coordinates AP
3.0, ML 2.0 and DV 3.0 mm [82]. CA1 was also identi-
fied by the electrophysiological recordings, guided by
the appearance of the large amplitude gamma oscilla-
tions (30 to 80 Hz) in local field potential (LFP) record-
ings. At the end of the experiments the animals were
sacrificed, the brains were removed and histology con-
firmed the localization of the electrodes in Nissl stained
sections [83].
Anaesthesia was induced by the intramuscular injec-
tion of a mixture of ketamine and xylazine (100 mg/kg
Figure 9 Validation of phasic and tonic currents recorded from CA1 pyramidal neurons at 0 mV holding potential as GABAergic
currents. (A) Voltage-clamp recording showing the elimination of both GABAergic IPSCs and GABAergic tonic current in the presence of 100 μM
picrotoxin in ACSF containing 30 μM Mg2+. (B) Holding current plotted at 1 s intervals during control condition (black), SNAP-5114 application
(red), washout (blue) and picrotoxin application (brown) in the same experiment.
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and 10 mg/kg, respectively) and maintained by repeated
(approximately every 30 minutes) intramuscular admin-
istration of the same substance. Body temperature was
kept at 37°C with a heating pad. The head was held by a
rat adaptor affixed to a stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA). Midline incision was
made on the scalp exposing the skull, followed by
retraction of the skin and craniotomy to expose a part
of the left hemisphere. The dura was left intact and
room temperature saline solution was used to prevent
desiccation.
A 23 channel laminar multi-electrode equipped with
two inner cannulae (40 μm diameter glass capillaries)
was used to record field potentials and to deliver the
testing solutions. The injector electrode was lowered
through the intact dura to target the CA1 region using
a microdrive. Interelectrode spacing was 150 μm, elec-
trode site diameter was 25 μm, shaft diameter was 350
μm, the drug delivery site was located between contacts
5 and 6 from the top (corresponding to current source
density channel 4 and 5 due to the fact that during cur-
rent source density computation the first and last chan-
nel is lost). The cannulae were attached to two
calibrated micrometer driven 5 μl Hamilton syringes
(Hamilton Company, Reno, NV, USA) via a 250 μm
inner diameter Tygon tube (Saint-Gobain, Akron, OH,
USA). Separate cannulae were carefully forward- and
back-filled with the testing solutions to avoid air bubbles
in the tubes.
LFP (0.03 Hz to 5,000 Hz) was recorded from each
of the contacts, sampled at 20 kHz/channel rate with
16 bit precision (LabView, National Instruments, Aus-
tin, TX, USA) and stored on a hard drive for off-line
analysis. Current source density (CSD) analysis identi-
fies synaptic/transmembrane generators of LFP, using
high-resolution maps of simultaneously recorded field
potentials obtained across a laminated neural structure.
Inhomogeneous conductivity was not taken into
account, second spatial derivative was calculated by the
nearest neighbour method, and high spatial frequency
noise was reduced by Hamming-window smoothing
[84,85]. Artefact free single sweep CSD epochs (256
ms long) were averaged (N = 1,000) in the frequency
domain using FFT to obtain the power spectrum for
all of the conditions. The CSD power spectra in the
str. radiatum of the CA1 before and after the testing
solution pressure injection (500 nl) were compared
using t-test, significance level was set to P = 0.005 (t =
2.57).
Double immunolabeling of GAT-3 and EAAT2
In the first step, an affinity-purified polyclonal antiserum
(rabbit anti-GAT-3, cat# AB1574, Chemicon, Temecula,
CA, USA) was applied to label GAT-3. The epitope for
the anti-GAT-3 antiserum was the C-terminus of rat
GAT-3 (aa 607 to 627) coupled to keyhole limpet hemo-
cyanin. No cross-reactivity to the C-termini of other
transmitter transporters was detected for the anti-GAT-
3 antiserum (see the manufacturer’s technical data
sheet). Subsequently, sections were immunolabeled for
EAAT2 using a monoclonal mouse anti-EAAT2 anti-
serum (mouse anti-EAAT2, cat# ab77039, Abcam, Cam-
bridge, UK).
The immunostaining was performed by using
Alexa594 labeled secondary antibody (cat# A21207, Life
Technologies, Grand Island, NY, USA) for GAT-3 fol-
lowed by FITC-tyramide fluorescent amplification
immunocytochemistry for EAAT-2. Briefly, free-floating
brain sections were pretreated in phosphate buffer (pH
= 7.4; PB) containing 0.5% Triton X-100 and 3% bovine
serum albumin for one hour. Then, they were incubated
with primary antibody against GAT-3 (1:50) in PB con-
taining 0.5% Triton X-100, 3% bovine serum albumin,
and 0.1% sodium azide for 48 hours at room tempera-
ture. Sections were then incubated in Alexa 594 donkey
anti-rabbit secondary antibody (1:400) for two hours.
After washing, the sections were incubated overnight in
the anti-EAAT-2 antibody followed by incubation in
biotin-conjugated donkey anti-mouse secondary anti-
body at 1:1,000 (Jackson ImmunoResearch, West Grove,
PA, USA) for two hours, followed by incubation in avi-
dinbiotin-horseradish peroxidase complex (ABC) at
1:500 (Vectastain ABC Elite kit, Vector, Burlingame,
CA, USA) for two hours. Then, sections were treated
with fluorescein isothiocyanate (FITC)-tyramide
(1:8,000) and 0.003% H2O2 in Tris-HCl buffer (0.05 M,
pH 8.2) for eight minutes, washed, mounted on posi-
tively charged slides (Superfrost Plus, Fisher Scientific,
Fair Lawn, NJ, USA), and cover-slipped in antifade med-
ium (Prolong Antifade Kit, Life Technologies, Grand
Island, NY, USA).
Sections were examined by using an Olympus BX60
light microscope (Olympus Corporation, Tokyo, Japan)
also equipped with fluorescent epi-illumination. Images
were captured at 2,048 × 2,048 pixel resolution with a
SPOT Xplorer digital CCD camera (Diagnostic Instru-
ments, Sterling Heights, MI, USA) using 4 to 40x objec-
tives. Confocal images were acquired at 1,024 × 1,024
pixel resolution with a Nikon Eclipse E800 confocal
microscope (Nikon Corporation, Tokyo, Japan) equipped
with a BioRad Radiance 2100 Laser Scanning System
(Bio-Rad Laboratories, Hercules, CA, USA) using 20 to
60x objectives at optical thicknesses of 1 to 5 μm. Con-
trast and sharpness of the images were adjusted by
using the levels and sharpness commands in Adobe
Photoshop CS 8.0 (Adobe Systems, San Jose, CA, USA).
Full resolution was maintained until the photomicro-
graphs were cropped and assembled for printing, at
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which point images were adjusted to a resolution of 300
dpi.
[Na+] monitoring in astrocytes
We used 250 μm hippocampal slices loaded with
sodium-binding benzofuranisophthalate (35 μM, Mole-
cular Probes) in the presence of 0.07% Pluronic-127
(Molecular Probes) in ACSF for one hour at 37°C.
Pluronic-127 was dissolved in DMSO. Astrocytes were
marked [40] by applying 1 μM sulforhodamin 101
(SR101) for 10 minutes at 37°C. To validate the mor-
phology of SR101-labelled cells, slices were imaged with
an Olympus FV300 laser scanning confocal microscope
system. Excitation was performed at 543 nm, emitted
light was filtered with a 560 to 600 nm bandpass filter.
Images were obtained by summation of optical sections
taken in the Z-axis, using ImageJ (NIH) software.
Conventional, wide-field fluorescence imaging was
performed using a digital imaging system (Olympus BX-
FLA) attached to an upright microscope (Olympus
BX50WI, 40x water immersion objective) and a CCD
camera as sensor (Princeton Micromax, Princeton
Instruments, Trenton, NJ, USA). Fluorescence excitation
wavelengths were selected by using a high-speed wave-
length switcher (Sutter Lambda DG-4, Sutter Instru-
ment, Novato, CA, USA). Image acquisition at 0.1 Hz
and time series were computer-controlled using the
software Metafluor.
For wide-field imaging with SBFI-AM at 37°C, fluores-
cence signals from astrocytes previously identified by
sulforhodamine 101 were collected at 525 nm (45 nm
bandwidth) after alternate excitation at 340 nm and at
380 nm, and the fluorescence ratio (F340/F380) was cal-
culated. At the end of some experiments an in situ cali-
bration was performed [86] by permeabilizing cells for
Na+ using gramicidin (6 μg/ml, Sigma, Sigma-Aldrich,
St. Louis, MO, USA) and monensin (10 μM, Sigma)
with simultaneous inhibition of the Na+/K+-ATPase
with ouabain (1 mM, Tocris) in a buffer containing 1.23
mM KH2PO4, 1.8 mM MgSO4, 1.6 mM CaCl2, 21 mM
KHCO3 and 10 mM glucose. Slices were then sequen-
tially perfused with solutions containing 0, 5, 10, 20 and
50 mM Na+, keeping (NaCl + choline-chloride) concen-
tration at 150 mM. A five-point calibration curve was
computed for each selected cell in the field of view and
used to convert fluorescence ratio values into Na+ con-
centrations. Baseline [Na+] was 4.3 ± 0.05 mM in aver-
age of 29 cells, Kd for SBFI was found to be 7.52 ± 0.82
mM.
Mass spectrometry
After pre-incubation for three to five hours in an inter-
face-type incubation chamber, seven 300 μm hippocam-
pal slices were placed on the bottom of a well in a 24-
well plate. Following one-hour incubation in 300 μl of
either normal ACSF or [Mg2+] = 1 μM ACSF, the bath
solution was removed and used as a measure of the
extracellular environment. The slices were transferred to
a micro tube. The remaining small amount of buffer
was removed from the tube and the slices were weighted
to obtain the wet tissue weight. In order to circumvent
the high background in GABA concentration measure-
ments due to the extreme level of GABA in neurotrans-
mitter vesicles, the slices were then subject to a mild
digestion procedure by freezing and thawing three times
for 10 minutes per cycle. This protocol is supposed to
selectively extract the cytosolic compartment leaving the
neurotransmitter vesicles intact. Using [3H] GABA to
selectively label the cytosolic or vesicular pools [87], we
verified that this procedure selectively extracts the cyto-
solic compartment. After the freezing-thawing cycles,
the fragmented membrane homogenate was centrifuged
at 61,000 g for 20 minutes and the supernatant was
used as a measure of the cytosolic environment. The
GABA concentration in these samples was found to be
approximately 1 mM, further confirming its cytosolic
origin.
The samples were separated prior to mass spectro-
metric analysis by a Perkin Elmer Series 200 Micro
HPLC system (Norwalk, CT, USA) consisting of a binary
pump, an autosampler and a column oven compart-
ment. The modified method of Eckstein [88] was used
where the mobile phase A was 1% formic acid and 0.5%
heptafluoro-butiric acid (HFBA) in water and mobile
phase B was 1% formic acid and 0.5% HFBA in acetoni-
trile. The column used was a Phenomenex Synergy
Hydro-RP 80A (Torrance, CA, USA) (150 × 3 mm, 4
μm). Oven temperature was 45°C. The initial mobile
phase composition was 100% A for 3.5 minutes then a
linear gradient was applied for 5.5 minutes to 90% B.
This was maintained for 1.0 minute and a quick linear
gradient back to 100% A for 0.5 minute was followed by
a 3.5 minutes equilibrium period. The overall run time
was 14.0 minutes. The flow rate of the mobile phase
was 500 μl/minute.
For quantitative analysis of compounds of interest an
AB Sciex 3200 Qtrap tandem mass spectrometer (AB
Sciex, Foster City, CA, USA) was used. The instrument
was run in positive electrospray multiple reaction moni-
toring (MRM) mode. The source conditions were: cur-
tain gas 20 l/minute, GS1 and GS2 50 and 40 l/minute,
respectively, temperature of the drying gas 500°C, spray
voltage 5000 V and the declustering potential was 20 V.
The MRM transitions and collision energies were (Q1/
Q3, CE) GABA 104/87, 20 ornithine 133/70, 20 and
putrescine 89/72, 25. The dwell time was 100 ms for all
transitions. Due to the different expected concentrations
of the target compounds in cytosolic and bath samples,
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different calibration points were used. A five-point cali-
bration curve was used in the range of 1 to 100 μM and
only 10 μl of samples were injected for cytosolic sam-
ples. For bath samples, a seven-point calibration curve
in range of 0.05 to 10 μM was used with injection
volume of 30 μl. The built-in quantitation module of
Analyst 1.5.1 software (Framingham, MA, USA) was
used for the quantitation.
The concentrations of the analytes were finally calculated
as pmol/mg wet tissue for both the cytosolic and the bath
samples. Molar GABA concentrations were estimated by
converting the pmol/mg values assuming 0.8 g/ml tissue
density and 0.17 as the ratio of extracellular/total volume.
Data evaluation
Unless stated otherwise data are expressed as means ±
S.E.M. and were analyzed using Student’s paired t-test
or one-way analysis of variances with Bonferroni post
hoc tests (OriginPro 8.0, OriginLab Coporation, North-
ampton, MA, USA). A value of P < 0.05 was considered
significant.
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